GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis

Reuters

06-26

GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis

GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis $(IPF.UK)$. The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-βɣ dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-25-000082), on June 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546560780"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546560780\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546560780?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546560780","market":"us","top_or_hot":-1,"title":"GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis <a href=\"https://laohu8.com/S/IPF.UK\">$(IPF.UK)$</a>. The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-βɣ dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-25-000082), on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-26 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis <a href=\"https://laohu8.com/S/IPF.UK\">$(IPF.UK)$</a>. The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-βɣ dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-25-000082), on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRI","symbol_name":"GRI BIO INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8Sq8HQ:1","article_id":"2546560780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546560780","pubTimestamp":1750939308,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis . The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-β dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRI":"GRI BIO INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"GRI Bio Inc.宣布GRI-0621治疗特发性肺纤维化的2a期研究取得积极的中期安全性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRI":0.9},"content_text":"GRI Bio Inc. Announces Positive Interim Safety Results from Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis\n    \n\n        GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis $(IPF.UK)$. The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-βɣ dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-25-000082), on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}